International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

Business Strategy: Re-Centering Ethics as Pharma’s Competitive Advantage

By Dirk Brinckman Chief Compliance Officer, Johnson & Johnson Chair, IFPMA Ethics and Business Integrity Committee Chair, ...
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)Opinion

17th meeting of the Conference of the Parties to the Convention on Biological Diversity (CBD COP17)

IFPMA submitted a statement at the start of the 17th meeting of the Conference of the Parties to the Convention on Biological ...
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)Opinion

Adoption of the Political Declaration on Pandemic Prevention, Preparedness, and Response (PPPR)

On 13 October 2026, on the occasion of the adoption of the Political Declaration on Pandemic Prevention, Preparedness, and ...
ifpma.org

Longer healthier lives, stronger economies: The potential for Europe’s preventive care agenda to set a global example

Longer life expectancy is one of the greatest successes of the last century. Since the 1960s alone, people in the European Union have gained, on average, more than two additional years of life per ...
ifpma.org

Consideration of the Political Declaration on Pandemic Prevention, Preparedness, and Response (PPPR)

On the occasion of the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response, Dr. David Reddy, Director General, IFPMA, said: “The global pharmaceutical industry urges governments ...
ifpma.org

Statement on PABS Instrument at the eighth meeting of the Intergovernmental Working Group (IGWG 8) on the WHO Pandemic Agreement

On 14 September 2026, IFPMA delivered a statement ahead of the eighth meeting of the Intergovernmental Working Group (IGWG 8) on the WHO Pandemic Agreement. One hundred days have passed since the ...
ifpma.org

76th WHO Regional Committee for Africa: Special update on the ongoing Ebola virus disease outbreak caused by Bundibugyo Virus

On 26 August, IFPMA delivered a statement on the special update on the ongoing Ebola virus disease outbreak caused by Bundibugyo Virus at the 76th session off the WHO Regional Committee for Africa in ...
ifpma.org

100 Day milestone of Ebola Bundibugyo outbreak must be a “wake up call” for pandemic preparedness, says pharma industry

100 days after the Ebola Bundibugyo outbreak was declared in the Democratic Republic of the Congo, the global pharmaceutical industry has underlined its track record and commitment to tackling health ...
ifpma.org

Statement on PABS Instrument at the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement

On 6 July 2026, IFPMA delivered a statement ahead of the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement. The extension of the negotiations provides an ...
ifpma.org

Pharmaceutical industry calls on G7 to invest in innovation to drive competitiveness, resilience, and growth

11 June 2026, GENEVA – PARIS – Ahead of the G7 Leaders’ Summit in Evian next week, the global pharmaceutical industry trade body – the International Federation of Pharmaceutical Manufacturers and ...
ifpma.org

Pharmaceutical industry’s response to the Ebola Bundibugyo virus disease outbreak

The latest Ebola Bundibugyo outbreak in Democratic Republic of Congo, Uganda, and neighbouring countries is deeply concerning. Pharmaceutical and biotech companies are working with global partners in ...